LETTER
Correction: Hepatitis Nomenclature
David K. H. Wong;
Angela M. Cheung;
Keith O'Rourke;
C. David Naylor;
Allan S. Detsky; and
Jenny Heathcote
1 November 1993 | Volume 119 Issue 9 | Page 957
Hyphenation may have caused some ambiguity in the recent article by Wong and colleagues [1]. The sentence "In summary, we have shown that 
-interferon is effective for the treatment of patients with chronic HBV infection and compensated liver disease who are HBsAg-, HBeAg-, and HBV DNA-positive and HIV-negative in the setting of clinical trials". should have read as follows: "In summary, we have shown that -interferon is effective for the treatment of patients with chronic HBV infection and compensated liver disease who are positive for HBsAg, HBeAg, and HBV DNA and negative for antibody to HIV in the setting of clinical trials".
1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of -interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 1993; 119:312-23.
About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Top
References
Article
